rpl-18 Antibody

What is RPL18 and why is it significant in research?

RPL18 (Ribosomal Protein L18) is a crucial component of the ribosomal large subunit, highly conserved across species with up to 85% amino acid similarity between humans and zebrafish . Its significance extends beyond protein synthesis to specialized roles in hematopoiesis, particularly erythroid development. Research indicates RPL18 deficiency can mirror the erythroid defects seen in Diamond-Blackfan anemia (DBA), characterized by a lack of mature red blood cells . Additionally, mutations in RPL18 have been identified in DBA patients, underscoring its clinical relevance. In immunological research, neo-epitopes encoded by point mutations in RPL18 have been shown to dominate CD8+ T cell responses in certain cancer models, positioning it as an important target for immunotherapy research .

How do polyclonal antibodies against RPL18 differ from monoclonal antibodies in research applications?

Polyclonal anti-RPL18 antibodies, such as those manufactured in Stockholm, Sweden, recognize multiple epitopes on the RPL18 protein, providing robust detection capabilities across varied experimental conditions . This multi-epitope recognition is particularly valuable when studying RPL18 under different conformational states or in different species due to the high conservation of the protein.

What validation methods should be expected for a high-quality RPL18 antibody?

A high-quality RPL18 antibody should undergo rigorous validation across multiple applications. The standard validation profile should include:

• Immunohistochemistry (IHC) validation with positive and negative tissue controls

• Immunocytochemistry/Immunofluorescence (ICC-IF) testing with subcellular localization confirmation

• Western blot (WB) validation showing bands of the expected molecular weight

• Cross-reactivity testing across relevant species

Advanced validation may include:

• Testing in RPL18 knockout or knockdown models to confirm specificity

• Mass spectrometry verification of immunoprecipitated protein

• Peptide competition assays

• Orthogonal validation using alternative antibodies or detection methods

High-quality RPL18 antibodies manufactured using standardized processes ensure rigorous quality control and reproducibility of results across different experimental batches .

How can RPL18 antibodies be utilized to study neo-epitope T cell responses in cancer models?

RPL18 antibodies play a critical role in studying neo-epitope T cell responses, particularly in cancer immunology. When investigating mutation-specific T cell responses, such as those against the MC-38 adenocarcinoma model, RPL18 antibodies can be employed in several methodological approaches:

• Immunoprecipitation coupled with mass spectrometry: RPL18 antibodies can isolate MHC-peptide complexes from tumor cells. In studies with the MC-38 tumor model, this approach helped identify a dominant neo-epitope encoded by a point-mutation in RPL18 sequence (KILTFDA to KILTFDRL) . The protocol involves:

  • Cell lysis in buffer containing 50 mM Tris-Cl pH 8.0, 150 mM NaCl, 5 mM EDTA, 0.5% Zwittergent

  • Sequential centrifugation to remove nuclei and insoluble material

  • Preclearance through a Sepharose column

  • Passage through antibody columns (anti-Kb, anti-Db)

  • Elution with 10% acetic acid and purification by SPE

  • Analysis by nanoHPLC MS/MS

• T cell response monitoring: After identifying RPL18 neo-epitopes, antibodies can be used in flow cytometry assays to monitor antigen-specific T cell responses. This involves:

  • Co-culture of T cells with peptide-loaded dendritic cells

  • Intracellular cytokine staining for TNFα and IFNγ

  • Tetramer staining to quantify antigen-specific T cells

This methodology has revealed that in some models, RPL18 neo-epitope-specific T cells strongly dominate the immune response compared to other neo-antigens, making them crucial targets for immunotherapeutic development .

What controls should be implemented when using RPL18 antibodies in T cell recognition assays?

When using RPL18 antibodies in T cell recognition assays, a comprehensive control strategy is essential to ensure reliable interpretation of results:

• Positive controls:

  • Known immunogenic peptides that elicit T cell responses

  • T cell lines with confirmed specificity for the target epitope

  • Polyclonal stimulation controls (e.g., PMA/ionomycin) to verify T cell functionality

• Negative controls:

  • Wild-type RPL18 peptide (non-mutated) to confirm specificity to the neo-epitope

  • Irrelevant peptides with similar binding affinity to the MHC

  • T cells from naive animals or non-immune subjects

• Technical controls:

  • Fluorescence-minus-one (FMO) controls for flow cytometry

  • Isotype control antibodies

  • Blocking controls using MHC-blocking antibodies to confirm MHC-restriction

• Validation controls:

  • Cross-validation using different detection methods (e.g., ELISPOT, tetramer staining, and intracellular cytokine staining)

  • Dose-response curves with peptide titrations

  • Time-course experiments to determine optimal assay timing

In studies with the MC-38 tumor model, researchers implemented direct tumor recognition assays by co-culturing T cells with irradiated MC-38 cells, alongside peptide stimulation assays with synthetic peptides representing the mutated region in RPL18. This dual approach provides validation of the physiological relevance of the T cell response to the neo-epitope .

How can RPL18 antibodies contribute to understanding Diamond-Blackfan anemia (DBA) pathogenesis?

RPL18 antibodies serve as critical tools for investigating the molecular mechanisms underlying Diamond-Blackfan anemia (DBA), a rare inherited bone marrow failure syndrome. Recent research has identified mutations in the RPL18 gene in DBA patients, establishing the protein as a candidate for pathogenesis studies . RPL18 antibodies contribute to DBA research through several methodological approaches:

The integrative use of RPL18 antibodies in these methodologies has revealed that inhibitors of JAK2 or STAT3 phosphorylation can rescue anemia in RPL18-deficient models, suggesting new therapeutic targets for DBA treatment .

What are the optimal methodologies for studying RPL18 in erythroid development using antibody-based techniques?

When investigating RPL18's role in erythroid development, researchers should employ a multi-faceted antibody-based approach to capture the complexity of developmental processes:

• Temporal expression profiling:

  • Perform western blot analysis at different developmental timepoints (24 hpf, 48 hpf, etc.)

  • Use immunohistochemistry to visualize spatial expression patterns in developing hematopoietic tissues

  • Complement protein detection with mRNA analysis through qRT-PCR and whole-mount in situ hybridization (WISH)

• Lineage-specific analysis:

  • Use flow cytometry with RPL18 antibodies alongside erythroid markers to quantify RPL18 expression in specific cell populations

  • Sort erythroid progenitors at different maturation stages to create expression profiles

  • Employ single-cell approaches to map RPL18 dynamics during differentiation

• Functional studies:

  • Use RPL18 antibodies to immunoprecipitate the protein complex from erythroid progenitors

  • Perform proximity ligation assays to identify stage-specific interaction partners

  • Conduct ChIP-seq to identify potential extraribosomal functions in gene regulation

• Pathway analysis:

  • Combine RPL18 antibodies with phospho-specific antibodies (pJAK2, pSTAT3) in multiplex assays

  • Utilize pharmacological inhibitors of JAK2-STAT3 pathway in conjunction with RPL18 detection

  • Correlate RPL18 expression with p53 activation markers to establish regulatory relationships

In zebrafish models, researchers have successfully combined these approaches to demonstrate that RPL18 deficiency leads to erythroid defects similar to those seen in DBA, with a significant increase in JAK2-STAT3 signaling activity, providing a methodological template for similar studies in other model systems .

How can RPL18 antibodies be used in immunoprecipitation for downstream peptide identification?

RPL18 antibodies can be strategically employed for immunoprecipitation (IP) procedures that facilitate downstream peptide identification, particularly in the context of MHC-presented neo-epitopes. This advanced application requires a methodical approach:

• Optimized immunoprecipitation protocol:

  • Cell lysis using specialized buffers (50 mM Tris-Cl pH 8.0, 150 mM NaCl, 5 mM EDTA, 0.5% Zwittergent 3-12) with protease inhibitors

  • Sequential centrifugation (10 min at 2500 × g, then 45 min at 31,000 × g) to remove nuclei and insoluble material

  • Sample preclearance through Sepharose column

  • Antibody column preparation by coupling anti-MHC antibodies (e.g., anti-Kb, anti-Db) to protein A Sepharose

  • Systematic washing with varying salt concentrations to reduce non-specific binding

  • Peptide elution with 10% acetic acid

• Sample preparation for mass spectrometry:

  • Dilution of eluted peptides with 0.1% TFA

  • Solid-phase extraction (SPE) purification

  • Sequential elution with increasing acetonitrile concentrations (20% and 30%)

  • Lyophilization and reconstitution in MS-compatible buffer

• Advanced mass spectrometry analysis:

  • On-line C18 nanoHPLC MS/MS analysis

  • Data-dependent acquisition for discovery approaches

  • Parallel reaction monitoring (PRM) for targeted quantification

  • Integration of heavy labeled peptide standards for absolute quantification

This methodology has successfully identified mutation-specific peptides from RPL18 in the MC-38 tumor model, revealing the KILTFDRL neo-epitope that dominates CD8+ T cell responses, demonstrating the powerful application of this technique in cancer immunology research .

What are the most effective protocols for troubleshooting non-specific binding when using RPL18 antibodies?

When encountering non-specific binding issues with RPL18 antibodies, researchers should implement a systematic troubleshooting approach:

• Antibody validation optimization:

  • Perform titration experiments to determine optimal antibody concentration

  • Test multiple blocking agents (BSA, normal serum, commercial blockers) to identify the most effective option

  • Increase blocking duration and concentration when high background persists

  • Consider using specialized blocking agents for specific applications (e.g., FcR blocking for flow cytometry)

• Buffer optimization strategies:

  • Adjust detergent type and concentration in washing buffers

  • Implement high-stringency washing steps with increasing salt concentrations

  • Use graduated washing protocols with decreasing detergent concentrations

  • Consider additives like polyvinylpyrrolidone or polyethylene glycol to reduce non-specific interactions

• Advanced controls and validation:

  • Include absorbed antibody controls (pre-incubated with recombinant RPL18)

  • Perform peptide competition assays with synthetic RPL18 peptides

  • Use samples from RPL18 knockout/knockdown models as negative controls

  • Employ isotype controls matched to the specific RPL18 antibody class and species

• Application-specific modifications:

  • For Western blots: Increase membrane blocking time and detergent in washing steps

  • For IHC/ICC: Optimize antigen retrieval methods and consider fluorescent secondary antibodies for better signal-to-noise ratio

  • For flow cytometry: Use viability dyes to exclude dead cells and implement doublet discrimination

  • For IP experiments: Add pre-clearing steps with Protein A/G beads and non-immune IgG

These systematic approaches have been successfully implemented in complex experiments involving RPL18 antibodies, such as in studies identifying neo-epitopes in tumor models, where minimizing non-specific binding is critical for accurate epitope identification .

How can RPL18 antibodies be utilized in developing personalized cancer vaccines?

RPL18 antibodies play an instrumental role in the development pipeline for personalized cancer vaccines, particularly those targeting neo-epitopes. The methodological framework includes:

• Neo-epitope discovery workflow:

  • Whole-exome sequencing of tumor and matched normal tissue to identify mutations

  • RNA sequencing to confirm expression of mutated transcripts

  • MHC class I peptide elution using anti-MHC antibodies

  • Mass spectrometry analysis to identify presented peptides

  • Confirmation of RPL18 mutation-derived epitopes using RPL18-specific antibodies

• Immunogenicity assessment protocol:

  • Synthetic peptide production based on identified mutations

  • In vitro T cell stimulation assays using peptide-loaded dendritic cells

  • Quantification of T cell responses via intracellular cytokine staining for TNFα and IFNγ

  • Tetramer staining to enumerate antigen-specific T cells

  • Direct tumor recognition assays to confirm physiological relevance

• Vaccine formulation optimization:

  • Testing various peptide lengths (minimal epitopes vs. longer peptides)

  • Evaluation of different adjuvants (e.g., CpG, TLR ligands)

  • Conjugation strategies to enhance immunogenicity

  • Prime-boost regimens to maximize response magnitude and durability

• Therapeutic efficacy evaluation:

  • Vaccination of tumor-bearing models with synthetic peptides covering the neo-epitope

  • Monitoring of tumor growth and survival outcomes

  • Analysis of vaccine-induced T cell responses in peripheral blood and tumor microenvironment

  • Assessment of epitope spreading and diversification of the immune response

Research with the MC-38 tumor model has demonstrated that vaccination with synthetic peptides containing the mutated RPL18 epitope induces CD8+ T cell responses that control tumor growth in vivo, highlighting the therapeutic potential of this approach. The RPL18 neo-epitope was found to strongly dominate the CD8+ T cell response compared to previously described neo-epitopes, emphasizing its immunological importance .

What are the methodological considerations when using RPL18 antibodies in investigating ribosomopathies and cancer?

When investigating the relationship between ribosomopathies (disorders of ribosome biogenesis) and cancer using RPL18 antibodies, researchers should consider these methodological approaches:

• Comprehensive expression profiling:

  • Quantitative immunohistochemistry across diverse cancer types and normal tissues

  • Tissue microarray analysis to correlate RPL18 expression with clinical outcomes

  • Single-cell protein analysis to detect heterogeneity within tumors

  • Correlation with genetic markers of ribosomopathies

• Functional impact assessment:

  • Co-immunoprecipitation to identify RPL18 interaction partners in cancer cells

  • Polysome profiling combined with RPL18 detection to assess ribosomal integration

  • Nucleolar stress response monitoring using p53 and nucleophosmin markers

  • Translation efficiency measurements for cancer-relevant mRNAs

• Signaling pathway integration:

  • Analysis of JAK2-STAT3 pathway activation in RPL18-deficient cancer models

  • Correlation between RPL18 levels and p53 activation patterns

  • Investigation of extraribosomal functions through subcellular localization studies

  • Targeted inhibition experiments combining ribosome biogenesis modulators with pathway inhibitors

• Therapeutic response prediction:

  • Using RPL18 antibodies as biomarkers for response to drugs targeting protein synthesis

  • Monitoring changes in RPL18 expression during treatment courses

  • Developing combination strategies targeting both ribosome biogenesis and downstream pathways (e.g., JAK2 inhibitors)

  • Patient stratification based on RPL18 expression patterns

The zebrafish model of RPL18 deficiency has demonstrated that loss of this ribosomal protein leads to increased p53 activation and JAK2-STAT3 activity, with inhibitors of these pathways rescuing the associated anemia . Similar approaches could be applied to cancer models to identify therapeutic vulnerabilities in tumors with altered RPL18 expression or function.

How should researchers interpret contradictory data between RPL18 antibody results and genetic expression analysis?

When faced with discrepancies between RPL18 antibody detection and genetic expression data, researchers should implement a systematic evaluation approach:

• Technical validation protocol:

  • Verify antibody specificity using multiple validation techniques (western blot, immunoprecipitation followed by mass spectrometry)

  • Test alternative antibody clones targeting different RPL18 epitopes

  • Confirm genetic expression using multiple methodologies (qRT-PCR, RNA-seq, WISH)

  • Perform time-course analyses to rule out temporal differences

• Post-transcriptional regulation assessment:

  • Investigate mRNA stability using actinomycin D chase experiments

  • Assess translation efficiency through polysome profiling

  • Examine protein stability with cycloheximide chase assays

  • Consider microRNA-mediated regulation through target prediction and validation

• Tissue-specific expression analysis:

  • Compare expression patterns across different cell types and tissues

  • Utilize single-cell approaches to detect heterogeneity in expression

  • Perform subcellular fractionation to assess protein localization

  • Consider context-dependent expression influenced by microenvironment

• Mutation impact evaluation:

  • For RPL18 mutations, determine if they affect epitope recognition by the antibody

  • Assess whether mutations impact protein stability without affecting mRNA levels

  • Consider nonsense-mediated decay for transcript reduction

  • Evaluate compensatory mechanisms that might stabilize protein despite reduced transcription

In zebrafish models, researchers observed that a 4bp deletion in the rpl18 gene led to a truncated protein of only 57 amino acids, with significantly downregulated rpl18 transcripts at both 24 and 48 hpf compared to controls. This was confirmed using multiple methods (qRT-PCR and WISH), demonstrating the importance of methodological triangulation when interpreting potentially contradictory data .

What are the optimal experimental designs for comparative studies using RPL18 antibodies across different species?

When designing comparative studies of RPL18 across species, researchers should implement a comprehensive experimental design that accounts for evolutionary conservation while addressing technical variables:

• Cross-species antibody validation strategy:

  • Select antibodies targeting highly conserved regions of RPL18 (85% amino acid similarity between human and zebrafish)

  • Perform western blot validation on each species to confirm specificity and appropriate molecular weight

  • Include peptide competition assays with species-specific RPL18 peptides

  • Consider generating species-specific antibodies for regions with significant divergence

• Standardized sample processing protocol:

  • Implement identical fixation and tissue processing methods across species

  • Use consistent antibody concentrations and incubation conditions

  • Process samples from different species in parallel to minimize technical variation

  • Incorporate quantitative standards for normalization across experiments

• Functional conservation analysis:

  • Compare RPL18 subcellular localization patterns across species

  • Assess binding partner conservation through comparative immunoprecipitation

  • Examine pathway responses (e.g., JAK2-STAT3, p53) to RPL18 deficiency across species

  • Evaluate complementation capacity through cross-species rescue experiments

• Quantitative comparison framework:

  • Develop standardized quantification metrics applicable across species

  • Utilize digital image analysis with consistent thresholding parameters

  • Implement normalization to conserved housekeeping proteins

  • Account for species-specific differences in tissue architecture and cellular composition

This design approach has been successfully implemented in studies comparing RPL18 function between zebrafish models and human samples, revealing conserved roles in erythropoiesis and similar pathogenetic mechanisms in Diamond-Blackfan anemia across species . Such comparative studies provide valuable insights into evolutionary conservation of RPL18 function while establishing the relevance of model organism findings to human disease.